Susquehanna International Group
SPRO icon

Susquehanna International Group’s Spero Therapeutics SPRO Stock Holding History

Susquehanna International Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Buy
+48,500
New +$115K ﹤0.01% 12252
2025
Q4 		– Sell
-10,900
Closed -$20.5K – 13551
2025
Q3 		$20.5K Sell
10,900
-37,800
-78% -$83.1K ﹤0.01% 12048
2025
Q2 		$141K Buy
+48,700
New +$70K ﹤0.01% 11543
2023
Q1 		– Sell
-22,700
Closed -$39.3K – 13452
2022
Q4 		$39.3K Sell
22,700
-101,200
-82% -$189K ﹤0.01% 11521
2022
Q3 		$248K Buy
+123,900
New +$123K ﹤0.01% 10289
2022
Q1 		– Sell
-15,000
Closed -$240K – 13923
2021
Q4 		$240K Sell
15,000
-18,500
-55% -$294K ﹤0.01% 11039
2021
Q3 		$617K Buy
33,500
+9,200
+38% +$148K ﹤0.01% 8850
2021
Q2 		$339K Sell
24,300
-28,400
-54% -$397K ﹤0.01% 10506
2021
Q1 		$776K Buy
52,700
+13,300
+34% +$234K ﹤0.01% 8388
2020
Q4 		$764K Buy
39,400
+12,300
+45% +$192K ﹤0.01% 7329
2020
Q3 		$302K Buy
+27,100
New +$321K ﹤0.01% 8693

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's SPRO Position: Q1 2026 in Review

Susquehanna International Group increased its Spero Therapeutics (SPRO) stake by 13% in Q1 2026, buying an estimated $93.5K and bringing the position to 333,115 shares worth $779K. The position accounts for ﹤0.01% of the portfolio, ranked #8536.

Susquehanna International Group first reported a position in SPRO in Q3 2019 and has held it in 22 quarters since. The position peaked at $1.44M in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Susquehanna International Group held 333,115 shares of Spero Therapeutics worth $779K as of Q1 2026.
  • Susquehanna International Group bought 39,415 Spero Therapeutics shares in Q1 2026, an estimated $93.5K.
  • Spero Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8536 holding.
  • Susquehanna International Group first reported a position in Spero Therapeutics in Q3 2019 and has held it in 22 quarters since.
  • Susquehanna International Group's Spero Therapeutics position peaked at $1.44M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.